Technical Analysis for VERV - Verve Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Earnings Movers | Other | 3.45% | |
| Wide Bands | Range Expansion | 3.45% | |
| Earnings Movers | Other | 2.11% | |
| Wide Bands | Range Expansion | 2.11% | |
| Wide Bands | Range Expansion | -1.87% | |
| Oversold Stochastic | Weakness | -1.87% | |
| 20 DMA Resistance | Bearish | -1.87% | |
| Shooting Star Candlestick | Bearish | -1.87% | |
| Doji - Bearish? | Reversal | -1.87% | |
| Wide Bands | Range Expansion | -1.87% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 1 hour ago |
| 1.5x Volume Pace | about 2 hours ago |
| Up 10% | about 2 hours ago |
| Up 1 ATR | about 2 hours ago |
| Rose Above 20 DMA | about 2 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Verve Therapeutics, Inc. Description
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.4199 |
| 52 Week Low | 5.84 |
| Average Volume | 1,365,838 |
| 200-Day Moving Average | 12.56 |
| 50-Day Moving Average | 10.40 |
| 20-Day Moving Average | 6.62 |
| 10-Day Moving Average | 6.19 |
| Average True Range | 0.59 |
| RSI (14) | 27.01 |
| ADX | 37.73 |
| +DI | 18.98 |
| -DI | 30.46 |
| Chandelier Exit (Long, 3 ATRs) | 7.00 |
| Chandelier Exit (Short, 3 ATRs) | 7.61 |
| Upper Bollinger Bands | 7.72 |
| Lower Bollinger Band | 5.52 |
| Percent B (%b) | 0.25 |
| BandWidth | 33.23 |
| MACD Line | -1.08 |
| MACD Signal Line | -1.29 |
| MACD Histogram | 0.203 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.53 | ||||
| Resistance 3 (R3) | 6.55 | 6.42 | 6.46 | ||
| Resistance 2 (R2) | 6.42 | 6.31 | 6.41 | 6.43 | |
| Resistance 1 (R1) | 6.25 | 6.23 | 6.19 | 6.23 | 6.40 |
| Pivot Point | 6.12 | 6.12 | 6.09 | 6.11 | 6.12 |
| Support 1 (S1) | 5.95 | 6.01 | 5.89 | 5.93 | 5.76 |
| Support 2 (S2) | 5.82 | 5.93 | 5.81 | 5.73 | |
| Support 3 (S3) | 5.65 | 5.82 | 5.71 | ||
| Support 4 (S4) | 5.63 |
